A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Stopped early · Phase 1

Conditions studied: Uveal Melanoma

In brief

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.

Key facts

Study ID

NCT02601378

Run by

Novartis Pharmaceuticals

People needed

107

Starts

2016-02-01

Expected to finish

2022-01-07

Last updated by the study team

2022-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Columbia University Medical Center — New York, New York, United States
• Novartis Investigative Site — Westmead, New South Wales, Australia
• Novartis Investigative Site — Paris, France
• Novartis Investigative Site — Leiden, Netherlands
• Novartis Investigative Site — Oslo, Norway
• Novartis Investigative Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.